Physician profile
John Alexander Wade
NPI 1215066873
$2,173.35
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $470 · 2021: $717 · 2022: $498 · 2023: $25.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $634.86 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $548.65 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.78 | 2019-2022 | |
| Glaxosmithkline, LLC. | $264.96 | 2019-2022 | |
| Optinose US, INC. | $128.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $120.42 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $47.50 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $31.85 | 2022 | |
| Amgen INC. | $30.24 | 2019 | |
| Genzyme Corporation | $29.49 | 2021-2022 | |
| Abbvie INC. | $25.90 | 2023 | Qulipta |
| Uswm, LLC | $19.36 | 2021 | |
| Circassia INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.